Lacosamida Intas (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This action stabilizes hyper‑excitable neurons, limits repetitive firing, and diminishes the spread of epileptiform activity, thereby contributing to seizure control.

The appropriate dose is determined by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and response to therapy. Initial dosing typically starts low and is titrated upward under medical supervision to achieve optimal seizure control.

Safety data for lacosamide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should evaluate the potential benefits against possible risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide differs from many traditional sodium channel blockers such as carbamazepine by selectively enhancing slow inactivation rather than fast inactivation. This mechanism may result in a distinct side‑effect profile and can be advantageous for patients who experience tolerability issues with other agents.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Lacosamida Intas is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome, cardiac conduction abnormalities like PR‑interval prolongation, suicidal ideation, significant hepatic injury, and rare blood disorders. Patients should be monitored closely for any of these signs and seek immediate medical attention if they occur.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, and those taking interacting medications that could increase toxicity.